Purpose: To investigate disorganization of retinal inner layers (DRIL) as a biomarker in eyes with diabetic macular oedema (DME) treated by intravitreal dexamethasone (DEX) implant. Methods: Multicentre, retrospective study including eyes with DME treated with DEX implant and follow-up of 12 months after the first injection.OCTscans were evaluated for the presence of DRIL and other structural features. Best corrected visual acuity (BCVA) and central subfield thickness (CST) were recorded at baseline and at 2, 4, 6 and 12 months after treatment. Correlation between DRIL at baseline and outcomes after DEX treatment and the change in DRIL were analysed. Results: Atotal of 177 eyes (177 patients; na€ıve, n = 131; refractory, n = 46) were included. Patients withoutDRILat baseline gained significantly more vision and enjoyed greater reduction in CST over 12 months (both p = 0.03). DRIL at the boundary between the ganglion cell-inner plexiform complex and inner nuclear layer improved in 48/64 eyes (75%, p < 0.001), while DRIL between the inner nuclear layer and outer plexiform layer improved in 27/77 eyes (35%, p = 0.004). Conclusions: This is the first study to show that DEX implant has the potential to ameliorate DRIL. Patients without DRIL at baseline have a favourable outcome. DRIL may serve a robust biomarker in DME treated by DEX implant.
Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant / D. Zur, M. Iglicki, A. Sala-Puigdollers, J. Chhablani, M. Lupidi, S. Fraser-Bell, T.S. Mendes, V. Chaikitmongkol, Z. Cebeci, D. Dollberg, C. Busch, A. Invernizzi, Z. Habot-Wilner, A. Loewenstein. - In: ACTA OPHTHALMOLOGICA. - ISSN 1755-375X. - (2019). [Epub ahead of print] [10.1111/aos.14230]
Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant
A. Invernizzi;
2019
Abstract
Purpose: To investigate disorganization of retinal inner layers (DRIL) as a biomarker in eyes with diabetic macular oedema (DME) treated by intravitreal dexamethasone (DEX) implant. Methods: Multicentre, retrospective study including eyes with DME treated with DEX implant and follow-up of 12 months after the first injection.OCTscans were evaluated for the presence of DRIL and other structural features. Best corrected visual acuity (BCVA) and central subfield thickness (CST) were recorded at baseline and at 2, 4, 6 and 12 months after treatment. Correlation between DRIL at baseline and outcomes after DEX treatment and the change in DRIL were analysed. Results: Atotal of 177 eyes (177 patients; na€ıve, n = 131; refractory, n = 46) were included. Patients withoutDRILat baseline gained significantly more vision and enjoyed greater reduction in CST over 12 months (both p = 0.03). DRIL at the boundary between the ganglion cell-inner plexiform complex and inner nuclear layer improved in 48/64 eyes (75%, p < 0.001), while DRIL between the inner nuclear layer and outer plexiform layer improved in 27/77 eyes (35%, p = 0.004). Conclusions: This is the first study to show that DEX implant has the potential to ameliorate DRIL. Patients without DRIL at baseline have a favourable outcome. DRIL may serve a robust biomarker in DME treated by DEX implant.File | Dimensione | Formato | |
---|---|---|---|
2019 - ACTA - Disorganization of inner retinal layers in diabetic patientis treated with dex implant.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
812.87 kB
Formato
Adobe PDF
|
812.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.